Agilent Technologies, Inc. $A Shares Purchased by Allworth Financial LP

Allworth Financial LP grew its stake in Agilent Technologies, Inc. (NYSE:A) by 11.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 7,325 shares of the medical research company’s stock after acquiring an additional 739 shares during the period. Allworth Financial LP’s holdings in Agilent Technologies were worth $864,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Resona Asset Management Co. Ltd. grew its position in Agilent Technologies by 6.2% during the second quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock valued at $11,631,000 after acquiring an additional 5,767 shares during the period. TrueMark Investments LLC purchased a new stake in Agilent Technologies during the 2nd quarter worth approximately $1,999,000. Fenimore Asset Management Inc boosted its stake in Agilent Technologies by 2.7% during the 2nd quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after acquiring an additional 4,823 shares during the last quarter. Nuance Investments LLC grew its stake in Agilent Technologies by 13.5% in the second quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock worth $9,523,000 after purchasing an additional 9,628 shares in the last quarter. Finally, Brighton Jones LLC grew its position in shares of Agilent Technologies by 89.5% in the 2nd quarter. Brighton Jones LLC now owns 9,068 shares of the medical research company’s stock worth $1,070,000 after acquiring an additional 4,284 shares in the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the transaction, the chief executive officer owned 33,448 shares of the company’s stock, valued at approximately $5,017,200. This represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.26% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on A shares. Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a report on Wednesday, October 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Wells Fargo & Company boosted their price target on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, September 15th. Finally, Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $149.62.

Agilent Technologies Trading Up 0.0%

Shares of NYSE:A opened at $146.90 on Friday. The company has a market cap of $41.65 billion, a P/E ratio of 34.48, a PEG ratio of 4.67 and a beta of 1.29. The stock’s fifty day moving average price is $137.63 and its 200-day moving average price is $123.77. Agilent Technologies, Inc. has a 1 year low of $96.43 and a 1 year high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the previous year, the company posted $1.32 earnings per share. Agilent Technologies’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th were given a $0.248 dividend. The ex-dividend date was Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a yield of 0.7%. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.